Teva Launches Co-Beneldopa (Levodopa/Benserazide)

CASTLEFORD, England, December 18 - Teva UK Limited has launched generic co-beneldopa capsules in a variety
of strengths. The company says that they are the first generic to reach the
market.

"We're delighted to be launching co-beneldopa capsules," said Kim Innes,
Commercial Director, Teva UK Limited. "This product fits well with our range
and strengthens our position as the UK's leading generics supplier. It comes
hot on the heels of diamorphine hydrochloride (HCL) powder for injection,
oxcarbazepine tablets and topiramate tablets which were added to our product
portfolio during the last quarter" she added.

Co-beneldopa is a dopaminergic drug indicated for treatment of symptoms
of Parkinson's disease(1). It is a generic version of Madopar(R) (co-
beneldopa) made by Roche. It is available immediately in the award-winning
Teva 360 livery, which is designed to aid patient safety, in the following
strengths and at these prices(2):

    - Co-Beneldopa capsules 50 mg / 12.5 mg x 100 GBP5.36
    - Co-Beneldopa capsules 100 mg / 25 mg x 100 GBP7.47
    - Co-Beneldopa capsules 200 mg / 50 mg x 100 GBP12.74

"At the moment over 50% of scripts are written by brand. If all scripts
were written and dispensed generically the potential saving to the NHS would
be over GBP341k annually(3)." said Kim Innes, Commercial Director, Teva UK
Limited.

References:

1) Co-beneldopa SmPC

2) Teva price list December 2009

3) Based on current price and reimbursement data - IMS Xponent NPA
Audit Sept 2009

About Teva UK Limited: Teva UK Limited is one of the UK's top ten
pharmaceutical manufacturers, with a presence in the generics, branded
respiratory and hospitals markets. It has the widest range of any UK generic
pharmaceutical company and markets solid and liquid dose, injectable and
respiratory medicines to healthcare professionals. The company is part of
Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) which has 38,000 employees
based in 70 countries around the world.

Note to Editors:

A picture accompanying this release is available through the PA
Photowire. It can be downloaded from www.pa-mediapoint.press.net or
viewed at www.mediapoint.press.net or www.prnewswire.co.uk.

For media enquiries, telephone the Teva Communications team on +44-(0)1977-628500, or email media.enquiries at tevauk.com.